Novel polymeric prodrug with multivalent components for cancer therapy

Area of Science:

• Polymer Chemistry
• Medicinal Chemistry
• Oncology

Background:

• Developing targeted drug delivery systems is crucial for improving cancer therapy efficacy.
• Polymeric prodrugs offer potential for enhanced drug solubility and targeted delivery.
• Luteinizing hormone-releasing hormone (LHRH) receptors are overexpressed on various cancer cells, making them attractive targets.

Purpose of the Study:

• To design and synthesize a novel targeted anticancer polymeric prodrug.
• To evaluate the in vitro and in vivo efficacy of the designed prodrug.
• To investigate the role of targeting moiety density on prodrug activity.

Main Methods:

• Synthesis of a bis(2-carboxyethyl) polyethylene glycol-based polymeric prodrug conjugated with LHRH peptide and camptothecin.
• In vitro cytotoxicity assays on cancer cell lines expressing LHRH receptors.
• In vivo antitumor activity studies in relevant animal models.
• Characterization of prodrug binding to LHRH receptors and intracellular drug delivery.

Main Results:

• The LHRH peptide moiety successfully bound to extracellular receptors and localized on cancer cell membranes.
• The prodrug enhanced the solubility of camptothecin and facilitated its delivery to the cytoplasm and/or nucleus.
• The prodrug with three copies of LHRH peptide and camptothecin exhibited nearly 100-fold greater cytotoxicity and superior antitumor efficacy compared to non-targeted or lower-copy versions.

Conclusions:

• The developed targeted polymeric prodrug effectively delivers camptothecin to LHRH receptor-expressing cancer cells.
• Increasing the density of the targeting moiety and drug significantly enhances anticancer potency.
• This novel prodrug strategy holds promise for improved cancer treatment outcomes.